| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.951 | 0.002 | 0.951 | Spasmolytic | 0.951 0.002 DBMET03252 0.951 0.002 DBMET03253 | ||
| 0.771 | 0.003 | 0.771 | Cholinergic antagonist | 0.771 0.003 DBMET03252 0.771 0.003 DBMET03253 | ||
| 0.75 | 0.003 | 0.75 | Acetylcholine antagonist | 0.75 0.003 DBMET03252 0.75 0.003 DBMET03253 | ||
| 0.708 | 0.003 | 0.708 | Acetylcholine M1 receptor antagonist | 0.708 0.003 DBMET03252 0.708 0.003 DBMET03253 | ||
| 0.689 | 0.004 | 0.689 | Psychostimulant | 0.689 0.004 DBMET03252 0.689 0.004 DBMET03253 | ||
| 0.686 | 0.003 | 0.686 | Acetylcholine muscarinic antagonist | 0.686 0.003 DBMET03252 0.686 0.003 DBMET03253 | ||
| 0.602 | 0.003 | 0.602 | Acetylcholine nicotinic antagonist | 0.602 0.003 DBMET03252 0.602 0.003 DBMET03253 | ||
| 0.604 | 0.017 | 0.604 | Toll-Like receptor agonist | 0.604 0.017 DBMET03252 0.604 0.017 DBMET03253 | ||
| 0.604 | 0.017 | 0.604 | Toll-Like receptor 7 agonist | 0.604 0.017 DBMET03252 0.604 0.017 DBMET03253 | ||
| 0.578 | 0.059 | 0.578 | Antiinflammatory | 0.578 0.059 DBMET03252 0.578 0.059 DBMET03253 | ||
| 0.55 | 0.037 | 0.55 | Analgesic | 0.55 0.037 DBMET03252 0.55 0.037 DBMET03253 | ||
| 0.502 | 0.015 | 0.502 | Cardiotonic | 0.502 0.015 DBMET03252 0.502 0.015 DBMET03253 | ||
| 0.47 | 0.005 | 0.47 | 5 Hydroxytryptamine uptake stimulant | 0.47 0.005 DBMET03252 0.47 0.005 DBMET03253 | ||
| 0.468 | 0.005 | 0.468 | Bronchodilator | 0.468 0.005 DBMET03252 0.468 0.005 DBMET03253 | ||
| 0.5 | 0.044 | 0.5 | Transcription factor NF kappa B inhibitor | 0.5 0.044 DBMET03252 0.5 0.044 DBMET03253 | ||
| 0.449 | 0.003 | 0.449 | Acetylcholine M2 receptor antagonist | 0.449 0.003 DBMET03252 0.449 0.003 DBMET03253 | ||
| 0.449 | 0.011 | 0.449 | Anesthetic general | 0.449 0.011 DBMET03252 0.449 0.011 DBMET03253 | ||
| 0.421 | 0.003 | 0.421 | Acetylcholine M3 receptor antagonist | 0.421 0.003 DBMET03252 0.421 0.003 DBMET03253 | ||
| 0.419 | 0.012 | 0.419 | Sodium/bile acid cotransporter inhibitor | 0.419 0.012 DBMET03252 0.419 0.012 DBMET03253 | ||
| 0.399 | 0.016 | 0.399 | P-glycoprotein inhibitor | 0.399 0.016 DBMET03252 0.399 0.016 DBMET03253 | ||
| 0.364 | 0.004 | 0.364 | Acetylcholine M4 receptor antagonist | 0.364 0.004 DBMET03252 0.364 0.004 DBMET03253 | ||
| 0.419 | 0.081 | 0.419 | Cyclophilin D inhibitor | 0.419 0.081 DBMET03252 0.419 0.081 DBMET03253 | ||
| 0.316 | 0.003 | 0.316 | Dopamine transporter inhibitor | 0.316 0.003 DBMET03252 0.316 0.003 DBMET03253 | ||
| 0.367 | 0.058 | 0.367 | Cholesterol antagonist | 0.367 0.058 DBMET03252 0.367 0.058 DBMET03253 | ||
| 0.317 | 0.011 | 0.317 | Anesthetic local | 0.317 0.011 DBMET03252 0.317 0.011 DBMET03253 | ||
| 0.316 | 0.015 | 0.316 | Alpha-N-acetylglucosaminidase inhibitor | 0.316 0.015 DBMET03252 0.316 0.015 DBMET03253 | ||
| 0.368 | 0.077 | 0.368 | Immunosuppressant | 0.368 0.077 DBMET03252 0.368 0.077 DBMET03253 | ||
| 0.311 | 0.038 | 0.311 | Anticonvulsant | 0.311 0.038 DBMET03252 0.311 0.038 DBMET03253 | ||
| 0.274 | 0.004 | 0.274 | Acetylcholine muscarinic agonist | 0.274 0.004 DBMET03252 0.274 0.004 DBMET03253 | ||
| 0.318 | 0.062 | 0.318 | Interleukin 2 agonist | 0.318 0.062 DBMET03252 0.318 0.062 DBMET03253 | ||
| 0.302 | 0.048 | 0.302 | Angiogenesis stimulant | 0.302 0.048 DBMET03252 0.302 0.048 DBMET03253 | ||
| 0.377 | 0.125 | 0.377 | Caspase 9 stimulant | 0.377 0.125 DBMET03252 0.377 0.125 DBMET03253 | ||
| 0.258 | 0.006 | 0.258 | Neuronal nicotinic receptor antagonist | 0.258 0.006 DBMET03252 0.258 0.006 DBMET03253 | ||
| 0.263 | 0.011 | 0.263 | Expectorant | 0.263 0.011 DBMET03252 0.263 0.011 DBMET03253 | ||
| 0.251 | 0.004 | 0.251 | Dopamine D5 antagonist | 0.251 0.004 DBMET03252 0.251 0.004 DBMET03253 | ||
| 0.245 | 0.004 | 0.245 | Acetylcholine M5 receptor antagonist | 0.245 0.004 DBMET03252 0.245 0.004 DBMET03253 | ||
| 0.26 | 0.027 | 0.26 | Cytidine deaminase inhibitor | 0.26 0.027 DBMET03252 0.26 0.027 DBMET03253 | ||
| 0.236 | 0.008 | 0.236 | Mucolytic | 0.236 0.008 DBMET03252 0.236 0.008 DBMET03253 | ||
| 0.234 | 0.01 | 0.234 | Acetylcholine agonist | 0.234 0.01 DBMET03252 0.234 0.01 DBMET03253 | ||
| 0.231 | 0.011 | 0.231 | Cyclooxygenase 3 inhibitor | 0.231 0.011 DBMET03252 0.231 0.011 DBMET03253 | ||
| 0.276 | 0.057 | 0.276 | Hypolipemic | 0.276 0.057 DBMET03252 0.276 0.057 DBMET03253 | ||
| 0.256 | 0.04 | 0.256 | Non-steroidal antiinflammatory agent | 0.256 0.04 DBMET03252 0.256 0.04 DBMET03253 | ||
| 0.218 | 0.003 | 0.218 | Acetylcholine M5 receptor agonist | 0.218 0.003 DBMET03252 0.218 0.003 DBMET03253 | ||
| 0.237 | 0.03 | 0.237 | Lipid peroxidase inhibitor | 0.237 0.03 DBMET03252 0.237 0.03 DBMET03253 | ||
| 0.271 | 0.065 | 0.271 | Tumour necrosis factor alpha release inhibitor | 0.271 0.065 DBMET03252 0.271 0.065 DBMET03253 | ||
| 0.206 | 0.011 | 0.206 | 5 Hydroxytryptamine uptake inhibitor | 0.206 0.011 DBMET03252 0.206 0.011 DBMET03253 | ||
| 0.289 | 0.096 | 0.289 | Antithrombotic | 0.289 0.096 DBMET03252 0.289 0.096 DBMET03253 | ||
| 0.194 | 0.006 | 0.194 | Adrenaline uptake inhibitor | 0.194 0.006 DBMET03252 0.194 0.006 DBMET03253 | ||
| 0.225 | 0.043 | 0.225 | Lipocortins synthesis antagonist | 0.225 0.043 DBMET03252 0.225 0.043 DBMET03253 | ||
| 0.193 | 0.015 | 0.193 | Histamine H1 receptor antagonist | 0.193 0.015 DBMET03252 0.193 0.015 DBMET03253 | ||
| 0.179 | 0.007 | 0.179 | Ca2+-transporting ATPase inhibitor | 0.179 0.007 DBMET03252 0.179 0.007 DBMET03253 | ||
| 0.179 | 0.008 | 0.179 | Dopamine uptake inhibitor | 0.179 0.008 DBMET03252 0.179 0.008 DBMET03253 | ||
| 0.175 | 0.007 | 0.175 | Acetylcholine release stimulant | 0.175 0.007 DBMET03252 0.175 0.007 DBMET03253 | ||
| 0.171 | 0.005 | 0.171 | Glycine receptor agonist | 0.171 0.005 DBMET03252 0.171 0.005 DBMET03253 | ||
| 0.246 | 0.081 | 0.246 | Interleukin agonist | 0.246 0.081 DBMET03252 0.246 0.081 DBMET03253 | ||
| 0.198 | 0.039 | 0.198 | ATPase inhibitor | 0.198 0.039 DBMET03252 0.198 0.039 DBMET03253 | ||
| 0.273 | 0.121 | 0.273 | Calcium channel activator | 0.273 0.121 DBMET03252 0.273 0.121 DBMET03253 | ||
| 0.23 | 0.083 | 0.23 | DNA synthesis inhibitor | 0.23 0.083 DBMET03252 0.23 0.083 DBMET03253 | ||
| 0.233 | 0.087 | 0.233 | Tyrosine 3 hydroxylase inhibitor | 0.233 0.087 DBMET03252 0.233 0.087 DBMET03253 | ||
| 0.237 | 0.095 | 0.237 | Gastrin inhibitor | 0.237 0.095 DBMET03252 0.237 0.095 DBMET03253 | ||
| 0.219 | 0.077 | 0.219 | Peptidyltransferase inhibitor | 0.219 0.077 DBMET03252 0.219 0.077 DBMET03253 | ||
| 0.284 | 0.148 | 0.284 | Antibacterial | 0.284 0.148 DBMET03252 0.284 0.148 DBMET03253 | ||
| 0.152 | 0.021 | 0.152 | Prolactin inhibitor | 0.152 0.021 DBMET03252 0.152 0.021 DBMET03253 | ||
| 0.166 | 0.036 | 0.166 | Adenylate cyclase inhibitor | 0.166 0.036 DBMET03252 0.166 0.036 DBMET03253 | ||
| 0.18 | 0.05 | 0.18 | Protein kinase stimulant | 0.18 0.05 DBMET03252 0.18 0.05 DBMET03253 | ||
| 0.253 | 0.125 | 0.253 | Vasodilator, peripheral | 0.253 0.125 DBMET03252 0.253 0.125 DBMET03253 | ||
| 0.15 | 0.021 | 0.15 | Toll-Like receptor 4 antagonist | 0.15 0.021 DBMET03252 0.15 0.021 DBMET03253 | ||
| 0.181 | 0.053 | 0.181 | Arachidonic acid antagonist | 0.181 0.053 DBMET03252 0.181 0.053 DBMET03253 | ||
| 0.241 | 0.116 | 0.241 | Nootropic | 0.241 0.116 DBMET03252 0.241 0.116 DBMET03253 | ||
| 0.22 | 0.097 | 0.22 | Superoxide dismutase inhibitor | 0.22 0.097 DBMET03252 0.22 0.097 DBMET03253 | ||
| 0.197 | 0.075 | 0.197 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.197 0.075 DBMET03252 0.197 0.075 DBMET03253 | ||
| 0.142 | 0.023 | 0.142 | Acetylcholine M3 receptor agonist | 0.142 0.023 DBMET03252 0.142 0.023 DBMET03253 | ||
| 0.247 | 0.137 | 0.247 | Vasodilator, coronary | 0.247 0.137 DBMET03252 0.247 0.137 DBMET03253 | ||
| 0.139 | 0.031 | 0.139 | Antineoplastic alkaloid | 0.139 0.031 DBMET03252 0.139 0.031 DBMET03253 | ||
| 0.288 | 0.181 | 0.288 | Apoptosis agonist | 0.288 0.181 DBMET03252 0.288 0.181 DBMET03253 | ||
| 0.15 | 0.044 | 0.15 | Cholesterol synthesis inhibitor | 0.15 0.044 DBMET03252 0.15 0.044 DBMET03253 | ||
| 0.161 | 0.056 | 0.161 | Cell wall synthesis inhibitor | 0.161 0.056 DBMET03252 0.161 0.056 DBMET03253 | ||
| 0.13 | 0.027 | 0.13 | Triose-phosphate isomerase inhibitor | 0.13 0.027 DBMET03252 0.13 0.027 DBMET03253 | ||
| 0.138 | 0.036 | 0.138 | Antihistaminic | 0.138 0.036 DBMET03252 0.138 0.036 DBMET03253 | ||
| 0.133 | 0.032 | 0.133 | Sphingomyelinase inhibitor | 0.133 0.032 DBMET03252 0.133 0.032 DBMET03253 | ||
| 0.12 | 0.02 | 0.12 | ATPase (Vacuolar H+) inhibitor | 0.12 0.02 DBMET03252 0.12 0.02 DBMET03253 | ||
| 0.252 | 0.154 | 0.252 | Histamine release inhibitor | 0.252 0.154 DBMET03252 0.252 0.154 DBMET03253 | ||
| 0.17 | 0.073 | 0.17 | Phospholipase C inhibitor | 0.17 0.073 DBMET03252 0.17 0.073 DBMET03253 | ||
| 0.117 | 0.019 | 0.117 | Nicotinic alpha4beta2 receptor antagonist | 0.117 0.019 DBMET03252 0.117 0.019 DBMET03253 | ||
| 0.146 | 0.049 | 0.146 | Alkylator | 0.146 0.049 DBMET03252 0.146 0.049 DBMET03253 | ||
| 0.116 | 0.024 | 0.116 | Analgesic, opioid | 0.116 0.024 DBMET03252 0.116 0.024 DBMET03253 | ||
| 0.106 | 0.018 | 0.106 | Estrogen-related receptor beta agonist | 0.106 0.018 DBMET03252 0.106 0.018 DBMET03253 | ||
| 0.204 | 0.118 | 0.204 | 5 Hydroxytryptamine release stimulant | 0.204 0.118 DBMET03252 0.204 0.118 DBMET03253 | ||
| 0.153 | 0.074 | 0.153 | Cholinergic | 0.153 0.074 DBMET03252 0.153 0.074 DBMET03253 | ||
| 0.118 | 0.039 | 0.118 | Histamine antagonist | 0.118 0.039 DBMET03252 0.118 0.039 DBMET03253 | ||
| 0.152 | 0.075 | 0.152 | Interferon gamma antagonist | 0.152 0.075 DBMET03252 0.152 0.075 DBMET03253 | ||
| 0.086 | 0.011 | 0.086 | 5-Alpha-reductase inhibitor | 0.086 0.011 DBMET03252 0.086 0.011 DBMET03253 | ||
| 0.187 | 0.112 | 0.187 | Aldehyde oxidase inhibitor | 0.187 0.112 DBMET03252 0.187 0.112 DBMET03253 | ||
| 0.085 | 0.011 | 0.085 | Nicotinic alpha3beta2 receptor antagonist | 0.085 0.011 DBMET03252 0.085 0.011 DBMET03253 | ||
| 0.165 | 0.092 | 0.165 | Platelet adhesion inhibitor | 0.165 0.092 DBMET03252 0.165 0.092 DBMET03253 | ||
| 0.193 | 0.124 | 0.193 | Immunostimulant | 0.193 0.124 DBMET03252 0.193 0.124 DBMET03253 | ||
| 0.19 | 0.122 | 0.19 | Antioxidant | 0.19 0.122 DBMET03252 0.19 0.122 DBMET03253 | ||
| 0.079 | 0.012 | 0.079 | Alpha-mannosidase inhibitor | 0.079 0.012 DBMET03252 0.079 0.012 DBMET03253 | ||
| 0.156 | 0.09 | 0.156 | Nitric oxide antagonist | 0.156 0.09 DBMET03252 0.156 0.09 DBMET03253 | ||
| 0.132 | 0.069 | 0.132 | Cyclooxygenase 1 inhibitor | 0.132 0.069 DBMET03252 0.132 0.069 DBMET03253 | ||
| 0.12 | 0.06 | 0.12 | Microtubule formation inhibitor | 0.12 0.06 DBMET03252 0.12 0.06 DBMET03253 | ||
| 0.078 | 0.018 | 0.078 | Nicotinic receptor alpha7 subunit antagonist | 0.078 0.018 DBMET03252 0.078 0.018 DBMET03253 | ||
| 0.178 | 0.119 | 0.178 | Platelet antagonist | 0.178 0.119 DBMET03252 0.178 0.119 DBMET03253 | ||
| 0.092 | 0.043 | 0.092 | Opioid kappa receptor antagonist | 0.092 0.043 DBMET03252 0.092 0.043 DBMET03253 | ||
| 0.067 | 0.018 | 0.067 | Nicotinic receptor alpha4 subunit antagonist | 0.067 0.018 DBMET03252 0.067 0.018 DBMET03253 | ||
| 0.067 | 0.018 | 0.067 | Glucose-6-phosphate translocase inhibitor | 0.067 0.018 DBMET03252 0.067 0.018 DBMET03253 | ||
| 0.063 | 0.015 | 0.063 | Mannosidase inhibitor | 0.063 0.015 DBMET03252 0.063 0.015 DBMET03253 | ||
| 0.103 | 0.056 | 0.103 | Creatine kinase inhibitor | 0.103 0.056 DBMET03252 0.103 0.056 DBMET03253 | ||
| 0.104 | 0.058 | 0.104 | Anabolic | 0.104 0.058 DBMET03252 0.104 0.058 DBMET03253 | ||
| 0.073 | 0.028 | 0.073 | Androgen agonist | 0.073 0.028 DBMET03252 0.073 0.028 DBMET03253 | ||
| 0.113 | 0.069 | 0.113 | 5 Hydroxytryptamine antagonist | 0.113 0.069 DBMET03252 0.113 0.069 DBMET03253 | ||
| 0.063 | 0.021 | 0.063 | Acetylcholine M1 receptor agonist | 0.063 0.021 DBMET03252 0.063 0.021 DBMET03253 | ||
| 0.056 | 0.013 | 0.056 | Nicotinic receptor beta4 subunit antagonist | 0.056 0.013 DBMET03252 0.056 0.013 DBMET03253 | ||
| 0.101 | 0.059 | 0.101 | UDP-glucose 4-epimerase inhibitor | 0.101 0.059 DBMET03252 0.101 0.059 DBMET03253 | ||
| 0.076 | 0.035 | 0.076 | Dopamine D1 antagonist | 0.076 0.035 DBMET03252 0.076 0.035 DBMET03253 | ||
| 0.177 | 0.138 | 0.177 | RNA-directed DNA polymerase inhibitor | 0.177 0.138 DBMET03252 0.177 0.138 DBMET03253 | ||
| 0.054 | 0.022 | 0.054 | Nicotinic receptor alpha3 subunit antagonist | 0.054 0.022 DBMET03252 0.054 0.022 DBMET03253 | ||
| 0.115 | 0.084 | 0.115 | DNA repair enzyme inhibitor | 0.115 0.084 DBMET03252 0.115 0.084 DBMET03253 | ||
| 0.147 | 0.118 | 0.147 | Succinate dehydrogenase inhibitor | 0.147 0.118 DBMET03252 0.147 0.118 DBMET03253 | ||
| 0.057 | 0.028 | 0.057 | 5 Hydroxytryptamine 4 antagonist | 0.057 0.028 DBMET03252 0.057 0.028 DBMET03253 | ||
| 0.073 | 0.045 | 0.073 | Phosphofructokinase-1 inhibitor | 0.073 0.045 DBMET03252 0.073 0.045 DBMET03253 | ||
| 0.101 | 0.076 | 0.101 | Cystathionine beta-synthase inhibitor | 0.101 0.076 DBMET03252 0.101 0.076 DBMET03253 | ||
| 0.051 | 0.028 | 0.051 | Glucose-6-phosphate isomerase inhibitor | 0.051 0.028 DBMET03252 0.051 0.028 DBMET03253 | ||
| 0.042 | 0.021 | 0.042 | Farnesoid X receptor agonist | 0.042 0.021 DBMET03252 0.042 0.021 DBMET03253 | ||
| 0.062 | 0.041 | 0.062 | Carbamoyl phosphate synthetase inhibitor | 0.062 0.041 DBMET03252 0.062 0.041 DBMET03253 | ||
| 0.074 | 0.056 | 0.074 | Na+ K+ transporting ATPase inhibitor | 0.074 0.056 DBMET03252 0.074 0.056 DBMET03253 | ||
| 0.116 | 0.098 | 0.116 | Vanilloid 1 agonist | 0.116 0.098 DBMET03252 0.116 0.098 DBMET03253 | ||
| 0.077 | 0.06 | 0.077 | Antineoplastic antibiotic | 0.077 0.06 DBMET03252 0.077 0.06 DBMET03253 | ||
| 0.126 | 0.11 | 0.126 | Adenylate cyclase stimulant | 0.126 0.11 DBMET03252 0.126 0.11 DBMET03253 | ||
| 0.061 | 0.047 | 0.061 | Beta 2 adrenoreceptor agonist | 0.061 0.047 DBMET03252 0.061 0.047 DBMET03253 | ||
| 0.081 | 0.068 | 0.081 | Opioid antagonist | 0.081 0.068 DBMET03252 0.081 0.068 DBMET03253 | ||
| 0.061 | 0.048 | 0.061 | Nitric oxide donor | 0.061 0.048 DBMET03252 0.061 0.048 DBMET03253 | ||
| 0.125 | 0.113 | 0.125 | Growth hormone agonist | 0.125 0.113 DBMET03252 0.125 0.113 DBMET03253 | ||
| 0.029 | 0.017 | 0.029 | 1,3-Beta-glucan synthase inhibitor | 0.029 0.017 DBMET03252 0.029 0.017 DBMET03253 | ||
| 0.056 | 0.044 | 0.056 | Lipocortins synthesis agonist | 0.056 0.044 DBMET03252 0.056 0.044 DBMET03253 | ||
| 0.063 | 0.051 | 0.063 | 5 Hydroxytryptamine 3A antagonist | 0.063 0.051 DBMET03252 0.063 0.051 DBMET03253 | ||
| 0.085 | 0.073 | 0.085 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.085 0.073 DBMET03252 0.085 0.073 DBMET03253 | ||
| 0.165 | 0.154 | 0.165 | Hypoglycemic | 0.165 0.154 DBMET03252 0.165 0.154 DBMET03253 | ||
| 0.034 | 0.027 | 0.034 | Ceramide glucosyltransferase inhibitor | 0.034 0.027 DBMET03252 0.034 0.027 DBMET03253 | ||
| 0.02 | 0.013 | 0.02 | 5-Alpha-reductase 2 inhibitor | 0.02 0.013 DBMET03252 0.02 0.013 DBMET03253 | ||
| 0.033 | 0.028 | 0.033 | HMG CoA reductase inhibitor | 0.033 0.028 DBMET03252 0.033 0.028 DBMET03253 | ||
| 0.124 | 0.119 | 0.124 | Pregnane X receptor agonist | 0.124 0.119 DBMET03252 0.124 0.119 DBMET03253 | ||
| 0.063 | 0.061 | 0.063 | Catalase inhibitor | 0.063 0.061 DBMET03252 0.063 0.061 DBMET03253 | ||
| 0.046 | 0.045 | 0.046 | Protein 50S ribosomal subunit inhibitor | 0.046 0.045 DBMET03252 0.046 0.045 DBMET03253 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |